Trials / Recruiting
RecruitingNCT06610799
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination with Oxaliplatin and Capecitabine (XELOX) in First-line Treatment of Unresectable Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Xiangdong Cheng · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI363 | IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W |
Timeline
- Start date
- 2024-10-15
- Primary completion
- 2025-06-30
- Completion
- 2026-12-31
- First posted
- 2024-09-24
- Last updated
- 2024-11-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06610799. Inclusion in this directory is not an endorsement.